ALK inhibitors in non-small cell lung cancer: the latest evidence and developments

著者: Sullivan, Ivana, Planchard, David
出版年 Ther Adv Med Oncol (2016)

Editorial on the article entitled “brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial”

著者: Sullivan, Ivana, Planchard, David
出版年 J Thorac Dis (2016)

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line

著者: Sullivan, Ivana, Planchard, David
出版年 Front Med (Lausanne) (2017)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer

著者: Mezquita, Laura, Planchard, David
出版年 Cancer Manag Res (2018)

Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience

著者: Sullivan, Ivana, Planchard, David
出版年 Ther Adv Respir Dis (2016)

Oncogene addiction and immune escape: friends or foes?

著者: Abdayem, Pamela, Planchard, David
出版年 Ann Transl Med (2020)

FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression

著者: Abdayem, Pamela, Planchard, David
出版年 Transl Lung Cancer Res (2020)

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience

著者: Botticella, Angela, Mezquita, Laura, Le Pechoux, Cecile, Planchard, David
出版年 Ther Adv Respir Dis (2019)

Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report

著者: Niu, Xiaomin, Sun, Yingjia, Planchard, David, Chiu, Luting, Bai, Jian, Ai, Xinghao, Lu, Shun
出版年 Front Oncol (2021)

Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib

著者: Facchinetti, Francesco, Levy, Antonin, Ammari, Samy, Naltet, Charles, Lavaud, Pernelle, Aldea, Mihaela, Vasseur, Damien, Planchard, David, Besse, Benjamin
出版年 Cancer Manag Res (2021)

Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer

著者: Schernberg, Antoine, Mezquita, Laura, Boros, Angela, Botticella, Angela, Caramella, Caroline, Besse, Benjamin, Escande, Alexandre, Planchard, David, Le Péchoux, Cécile, Deutsch, Eric
出版年 PLoS One (2018)

Staging of nutrition disorders in non‐small‐cell lung cancer patients: utility of skeletal muscle mass assessment

著者: Antoun, Sami, Morel, Hugues, Souquet, Pierre‐Jean, Surmont, Veerle, Planchard, David, Bonnetain, Franck, Foucher, Pascal, Egenod, Thomas, Krakowski, Ivan, Gaudin, Hélène, Debieuvre, Didier
出版年 J Cachexia Sarcopenia Muscle (2019)

ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer

著者: Passaro, Antonio, Addeo, Alfredo, Von Garnier, Christophe, Blackhall, Fiona, Planchard, David, Felip, Enriqueta, Dziadziuszko, Rafal, de Marinis, Filippo, Reck, Martin, Bouchaab, Hasna, Peters, Solange
出版年 ESMO Open (2020)

Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non–Small Cell Lung Cancer

著者: Kas, Baptiste, Talbot, Hugues, Ferrara, Roberto, Richard, Colombe, Lamarque, Jean-Philippe, Pitre-Champagnat, Stéphanie, Planchard, David, Balleyguier, Corinne, Besse, Benjamin, Mezquita, Laura, Lassau, Nathalie, Caramella, Caroline
出版年 JAMA Oncol (2020)

Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients

著者: Boros, Angela, Lacroix, Ludovic, Lacas, Benjamin, Adam, Julien, Pignon, Jean-Pierre, Caramella, Caroline, Planchard, David, de Montpreville, Vincent, Deutsch, Eric, Levy, Antonin, Besse, Benjamin, Pechoux, Cécile Le
出版年 Oncotarget (2017)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

著者: Oulhen, Marianne, Pawlikowska, Patrycja, Tayoun, Tala, Garonzi, Marianna, Buson, Genny, Forcato, Claudio, Manaresi, Nicolò, Aberlenc, Agathe, Mezquita, Laura, Lecluse, Yann, Lavaud, Pernelle, Naltet, Charles, Planchard, David, Besse, Benjamin, Farace, Françoise
出版年 NPJ Precis Oncol (2021)

A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer

著者: Yamamoto, Nobuyuki, Hayashi, Hidetoshi, Planchard, David, Morán, Teresa, Gregorc, Vanesa, Dowell, Jonathan, Sakai, Hiroshi, Yoh, Kiyotaka, Nishio, Makoto, Cortot, Alexis B., Benhadji, Karim A., Soni, Nital, Huang, Jinhong, Makris, Lukas, Cedres, Susana
出版年 Invest New Drugs (2020)

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer

著者: Park, Wungki, Mezquita, Laura, Okabe, Naoyuki, Chae, Young Kwang, Kwon, Deukwoo, Saravia, Diana, Auclin, Edouard, Planchard, David, Caramella, Caroline, Ferrara, Roberto, Agte, Sarita, Oh, Michael, Mudad, Raja, Jahanzeb, Mohammad, Suzuki, Hiroyuki, Besse, Benjamin, Lopes, Gilberto
出版年 Br J Cancer (2019)

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay

著者: Remon, Jordi, Swalduz, Aurelie, Planchard, David, Ortiz-Cuaran, Sandra, Mezquita, Laura, Lacroix, Ludovic, Jovelet, Cecile, Rouleau, Etienne, Leonce, Camille, De Kievit, Frank, Morris, Clive, Jones, Greg, Mercier, Kelly, Howarth, Karen, Green, Emma, Pérol, Maurice, Saintigny, Pierre, Besse, Benjamin
出版年 PLoS One (2020)

An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer

著者: Planchard, David, Besse, Benjamin, Groen, Harry J M, Souquet, Pierre-Jean, Quoix, Elisabeth, Baik, Christina S, Barlesi, Fabrice, Kim, Tae Min, Mazieres, Julien, Novello, Silvia, Rigas, James R, Upalawanna, Allison, D’Amelio, Anthony M, Zhang, Pingkuan, Mookerjee, Bijoyesh, Johnson, Bruce E
出版年 Lancet Oncol (2016)